

31

32 Biyun Zhang,

33 Professor

34 Central laboratory, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer

35 Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi

36 Medical University, Taiyuan, 030013, China.

37 Tel: 86-18406593082

38 E-mail: z18406593082@163.com

39

40 Yongqiang Lv MD, PhD

41 Professor

42 Department of Quality Control, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to

43 Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to

44 Shanxi Medical University, Taiyuan, China.

45 E-mail: lyq820529@163.com

46 **Abstract**

47 Previous studies have linked blood cell traits (BCTs) to cardiovascular diseases
48 (CVDs) risks, but the common genetic mechanisms underlying heritable phenotypes
49 remain unclear. Our study used multiple analytical approaches including single
50 nucleotide polymorphisms, genes, pathways, and protein targets to reveal common
51 genetic elements. We confirmed both genome-wide and local genetic associations
52 between BCTs and CVDs, identifying key pleiotropic loci and genes contributing to
53 these links. Specifically, *ALDH2*, *MAPKAPK5*, and *ACAD10*, all located at 12q24.1,
54 are associated with leukocyte-CVD traits. *TNFSF12* at 17p13.1 and *ABO* at 9q34.2
55 correlate with platelet-CVD traits, while *ZNF664* and *CCDC92*, also at 12q24.1, are
56 linked to erythrocyte-CVD traits. Our findings also highlight multiple key
57 trait-specific pathways mediating these phenotypic associations and potential
58 therapeutic targets that may inform future clinical interventions. These insights
59 significantly advance our understanding of the genetic interplay between BCTs and
60 CVDs, underscoring the importance of focusing on BCTs to prevent cardiovascular
61 conditions.

62

63 **Keywords**

64 Blood cell traits, Cardiovascular disease, Shared genetic architectures, Genetic
65 correlation, Genome-wide association studies, Pleiotropic analysis.

66

67 **Highlights**

- 68 ● There were wide genetic correlation and overlap between BCT and CVD.
- 69 ● Key pleiotropic loci and genes for three BCT-CVD trait pairs were identified.
- 70 ● Key signature-specific pathways mediating the BCTs-CVDs association were
71 identified.
- 72 ● Potential therapeutic targets for BCTs-CVDs were identified.

73

74 **eTOC blurb**

75 Kong et al. report extensive genetic correlations and genetic overlaps between blood
76 cell traits (BCTs) and cardiovascular diseases (CVDs), revealing key pleiotropic loci
77 and genes contributing to these associations, as well as multiple trait-specific
78 pathways mediating these phenotypic associations. Potential therapeutic targets to
79 inform future clinical interventions were also identified, laying the foundation for
80 understanding the genetic interactions between BCTs and CVDs.

81

82 **Introduction**

83 Cardiovascular diseases (CVDs), which encompass a range of conditions affecting the
84 heart and blood vessels, are the leading cause of death and disability worldwide^{1,2}. A
85 primary contributor to CVDs, atherosclerosis, is significantly influenced by various
86 blood cell traits (BCTs)^{3,4}. For example, erythrocytes, critical in maintaining
87 physiological hemodynamics, can exacerbate arterial wall pathologies and, through
88 interactions with immune cells, potentially accelerate atherosclerosis due to oxidative
89 stress⁵. Similarly, the secretory functions of leukocytes, especially lymphocytes, are
90 pivotal as they release proinflammatory cytokines and proteases that may lead to
91 plaque rupture⁶. Platelets also play a key role in hemostasis and thrombosis and
92 enhancing the inflammatory environment, thus promoting the recruitment of
93 inflammatory cells to lesions and releasing inflammatory mediators⁷. Extensive
94 observational research has consistently demonstrated a robust association between
95 alterations in BCTs and increased risk of CVDs. Recent studies have identified
96 erythrocyte count (RBC), hematocrit (HCT), mean corpuscular volume (MCV), and
97 red cell distribution width (RDW-CV) as potential biomarkers for cardiovascular
98 risk⁸. Additionally, conditions characteristic of CVDs can prompt the bone marrow to
99 release immature cells or increase other cell populations, depending on the severity.
100 Notably, the leukocyte is a cost-effective, widely used diagnostic tool in clinical
101 practice, with insights from the Framingham Heart Study highlighting its role as an
102 indicator of elevated CVD risks⁹. More precise predictions of CVD risk come from
103 specific leukocyte subtypes, such as monocytes¹⁰, lymphocytes¹¹, and neutrophils¹²,
104 rather than total leukocyte count (WBC) alone. Furthermore, studies have shown that

105 platelet metrics like platelet component distribution width (PDW), mean platelet
106 volume (MPV), and platelet count (PLT) are critical indicators of CVD risk¹³. These
107 insights underscore the importance of monitoring alterations in blood cell functions
108 for effective diagnosis, risk stratification, and predicting outcomes in CVDs.

109

110 Epidemiological studies have consistently shown that BCTs are closely associated
111 with CVDs, with this relationship likely influenced by shared genetic factors^{14,15}.

112 Genome-wide association studies (GWAS) have identified numerous genetic variants
113 common to both BCTs and CVDs, such as *SH2B3* and *HFE*, which are associated
114 with RBC and coronary artery disease (CAD), respectively¹⁶⁻¹⁸. This suggests that

115 pleiotropy, the influence of a single genetic variant on multiple traits, may be
116 fundamental to understanding the genetic basis of these complex traits. Pleiotropy

117 manifests in two primary forms: vertical and horizontal¹⁹. Vertical pleiotropy occurs
118 when single nucleotide polymorphisms (SNPs) influence one trait, which
119 subsequently affects another, permitting the use of Mendelian randomization (MR) to

120 estimate causal relationships between traits. For example, Hashfield *et al.*
121 demonstrated a positive causal relationship between PLT and eosinophil percentage of

122 leukocytes (EO_P) with an increased risk of ischemic stroke and its subtypes²⁰.

123 Similarly, genetic predispositions towards high RBC and low monocyte count
124 (MONO) correlate with increased venous thromboembolism (VTE) risk²¹. However,

125 existing MR studies have yet to explore these trait categories fully. On the other hand,
126 horizontal pleiotropy occurs when a genetic variant independently affects multiple

127 phenotypes or influences intermediate processes between these phenotypes. Recent
128 advances in statistical tools for genomics have underscored the importance of

129 horizontal pleiotropy in elucidating the shared genetic basis of complex traits. For
130 example, Yang *et al.* reported an extensive landscape of genetic correlations between

131 29 BCTs and 11 neurological and psychiatric diseases²². Despite these insights,
132 previous studies have yet to comprehensively explore the relationship between BCTs

133 and CVDs. The complex association patterns and underlying mechanisms of their
134 connection remain largely uncharted. Therefore, systematic analyses are necessary to

135 determine whether shared genetic architectures and molecular pathways exist between
136 BCTs and CVDs, potentially unveiling new insights into their biological mechanisms.

137

138 In this study, we comprehensively analyzed the latest and most extensive GWAS
139 summary data from individuals of European ancestry to uncover the shared genetic
140 architecture and mechanisms underlying 29 BCTs and six major CVDs (Table 1). Our
141 initial analyses focused on identifying the shared genetic structure between BCTs and
142 CVDs, utilizing methods to analyze genetic correlations and overlaps. Then,
143 employing MR analysis within a framework of vertical pleiotropy, we explored
144 evidence for causal relationships between BCTs and CVDs. This groundwork
145 facilitated a cross-trait analysis, pinpointing pleiotropic SNPs at the SNP level, and
146 allowed us to identify candidate pleiotropic genes through positional mapping and
147 expression quantitative trait loci (eQTL) mapping. Further investigations included an
148 enrichment analysis of biological pathways and the identification of pathogenic
149 plasma proteins, assessing their potential as therapeutic targets. This multifaceted
150 approach has illuminated complex genetic networks linking hematological markers to
151 cardiovascular health, offering insights that could pave the way for novel diagnostic
152 and therapeutic strategies.

153

154 **Result**

155 **Genome-wide genetic correlation between BCTs and CVDs**

156 We assessed the SNP-based heritability (h^2_{SNP}) of 29 BCTs and 6 major CVDs using
157 linkage disequilibrium (LD) score regression (LDSC) and performed genome-wide
158 genetic correlation (r_g) analysis of these 174 trait pairs. Univariate LDSC analysis
159 showed that h^2_{SNP} estimates for BCTs were consistently higher than those for CVDs,
160 ranging from 5.2% to 34.9%, with the highest estimate for MPV ($h^2_{SNP} = 34.88\%$, SE
161 = 0.036). In contrast, h^2_{SNP} estimates for CVDs were significantly lower, all below 5%,
162 with the smallest estimate for Stroke ($h^2_{SNP} = 0.60\%$, SE = 0.0005) and the highest
163 estimate for CAD ($h^2_{SNP} = 3.25\%$, SE = 0.0019) (Supplementary Table 1). Subsequent
164 bivariate LDSC analysis found nominally significant associations for 36 (20.3%) of

165 174 trait pairs ($P < 0.05$). Of these, 26 trait pairs showed positive r_g , especially
166 between WBC and PAD, with a r_g of 0.115 (SE = 0.053). In contrast, the most
167 significant negative r_g was between mean corpuscular hemoglobin concentration
168 (MCHC) and VTE, with a r_g of -0.101 (SE = 0.028). Using a less stringent 5% false
169 discovery rate (FDR) threshold, we found that three blood cell count-related traits,
170 including platelet crit (PCT), PLT, and MCHC, were associated with a lower risk of
171 VTE. Six different BCTs (neutrophil count (NEUT), WBC, high light scatter
172 reticulocyte count (HLR), high light scatter percentage of red cells (HLR_P),
173 reticulocyte count (RET), and reticulocyte fraction of red cells (RET_P)) were
174 significantly associated with an increased risk of CAD. In contrast, six different BCTs
175 (immature fraction of reticulocytes (IRF), mean corpuscular hemoglobin (MCH),
176 MCV, mean reticulocyte volume (MRV), mean spheric corpuscular volume (MSCV),
177 and red cell distribution width (RDW_CV) were significantly associated with an
178 increased risk of VTE. Notably, four trait pairs previously identified as having the
179 same direction of genetic correlations (including HLR-CAD, MRV-VTE, MCV-VTE,
180 and RDW_CV-VTE) confirmed significant correlations between them^{21,23-26} (Fig. 1
181 and Supplementary Table 2).

182

183 **Local genetic correlation between BCTs and CVDs**

184 LDSC is used to estimate additive genetic effects on traits across the genome,
185 however, when genetic signals show opposite correlations in different genomic
186 regions, the cumulative genome-wide r_g can asymptotically approach zero. To address
187 this issue, we used Local Analysis of [co] Variant Annotation (LAVA) to perform
188 more detailed analyses within shorter genomic regions, specifically focusing on local
189 genetic correlations (local- $r_{g,s}$) between 29 BCTs and 6 CVDs. Applying it to 80,126
190 regions, we identified 28,887 univariate genetic signals associated with BCTs in 2,219
191 unique regions and 2,716 signals associated with CVDs in 1,472 unique regions, all
192 with p-values less than 1×10^{-4} (Supplementary Table 3). Subsequent bivariate analysis
193 revealed significant local- $r_{g,s}$ (FDR < 0.05) for all trait pairs, covering 5,233 genetic
194 regions (including 898 unique regions)(Supplementary Fig.1 and Supplementary

195 Table 4). Interestingly, there is mixed local genetic effects on trait pairs where
196 genome-wide r_g is not significant. For example, between MSCV and CAD, 41.4% of
197 the partitions showed positive associations, 59.6% showed negative associations,
198 suggesting that genome-wide r_g may underestimate the polygenic overlap of these
199 trait pairs. Notably, LD block 1841 on chromosome 12 was associated with more than
200 half of the trait pairs, followed by LD block 1479 on chromosome 9 and LD block
201 1480 on chromosome 12, which showed correlations with 68 and 47 trait pairs,
202 respectively. Then, Hypothesis Prioritisation for multi-trait Colocalization
203 (HyPrColoc) further identified the common causal variants among them and indicated
204 a high association frequency for pleiotropic SNPs in the 12q24.12 region. Notably,
205 rs3184504 (mapped to the *SH2B3* gene) showed strong evidence of colocalization
206 between 19 BCTs and 2 CVDs (CAD and VTE) , with a posterior probability (PP) >
207 0.7. In addition, rs4378452 (mapped to the *CUX2* gene) was identified as a potential
208 common causal variable between 22 BCTs and CAD.

209

210 **Extensive genetic overlap between BCTs and CVDs**

211 Consider that r_g can not characterize detailed association patterns at individual loci,
212 and nonsignificant estimates do not necessarily indicate the absence of a common
213 genetic background. Therefore, we further applied genetic analysis combining
214 pleiotropy and annotation (GPA) approach to explore the overlapping genetic variants
215 of 29 BCTs and 6 CVDs, enhancing the understanding of the common genetic
216 landscape of BCTs and CVDs. GPA analysis revealed that all BCTs-CVDs trait pairs
217 exhibited varying degrees of genetic overlap at a 5% FDR threshold, regardless of
218 whether the genome-wide r_g was significant (Supplementary Fig.2 and Supplementary
219 Table 5). Notably, reticulocyte count (RET) and CAD showed a relatively high
220 proportion of shared SNPs (proportion of association ratio (PAR) = 25.4%), consistent
221 with their significant genetic correlation ($r_g = 0.107$). Among the 138 BCTs-CVDs
222 pairs with non-significant genome-wide r_g , the overlap between CAD and MSCV was
223 particularly pronounced, with a shared genetic overlap of 24.1%. As for IRF-VTE, as
224 a significant genome-wide r_g trait pair, the proportion of pleiotropic SNPs is only

225 19.0%, which is lower than MSCV-CAD. In summary, we confirmed the presence of
226 shared genetic structure in all trait pairs using LAVA and GPA approaches. Although
227 some trait pairs did not show evidence of genome-wide r_g , possibly due to
228 confounding effects, our analyses highlight potential genetic links that contribute to
229 the complex relationship between BCTs and CVDs.

230

231 **Mendelian Randomization between BCTs and CVDs**

232 To investigate vertical pleiotropy between 29 BCTs and 6 CVDs, we employed Latent
233 Heritable Confounder Mendelian Randomization (LHC-MR) to evaluate causal
234 relationships. The forward analysis identified seven causal relationships that achieved
235 Bonferroni-corrected significance, including positive associations for RDW-VTE,
236 basophil percentage of leukocytes (BASO_P)-AF, and BASO_P-CAD. For example,
237 an elevated RDW_CV was associated with an increased risk of VTE (OR = 1.08),
238 whereas a higher IRF was linked to a reduced risk of CAD (OR = 0.91), indicating
239 negative causal relationships. The reverse analysis uncovered twelve positive causal
240 relationships, such as AF, with an increased MCV (OR = 1.52). In contrast, four pairs
241 showed negative causal relationships, notably VTE associated with a decreased
242 RDW_CV (OR = 0.71). Remarkably, only the pair PCT-CAD exhibited a bidirectional
243 causal relationship. These findings suggest that although some trait pairs demonstrate
244 distinct causal connections, most associations between BCTs and CVDs are not driven
245 by underlying causal factors (Fig. 2, Supplementary Fig. 3, Supplementary Table 6 and
246 Supplementary Table 7).

247

248 **Shared Loci between BCTs and CVDs**

249 Although the above three approaches have enhanced our understanding of the general
250 pleiotropy between BCTs and CVDs, they still need to elaborate on the association
251 patterns of individual loci and clarify their shared genetic architecture from the
252 perspective of vertical and horizontal pleiotropy. To fill this gap, we employed the
253 Pleiotropic Analysis under the Composite Null Hypothesis (PLACO) to identify
254 horizontal pleiotropic SNPs mediating the association between BCTs and CVDs. A

255 total of 571,782 SNPs ($P < 5 \times 10^{-8}$) were identified as significant pleiotropic variants
256 across all BCT-CVD pairs (Fig. 3 and Supplementary Table 8). Notably, the PLT-CAD
257 pair exhibited the most pleiotropic associations with 176 pleiotropic SNPs, followed
258 closely by RBC-CAD (173 pleiotropic SNPs) and MSCV-CAD (168 pleiotropic
259 SNPs), consistent with the significant genetic overlap between these trait pairs.
260 Subsequently, 571,782 pleiotropic SNPs were clustered into 13,697 genomic loci in
261 580 unique chromosomal regions using functional mapping and annotation (FUMA).
262 Specifically, 11,810 loci were associated with BCTs, 3,904 with CVDs, and 2,622
263 were shared between BCTs and CVDs. Notably, 12 chromosomal regions were shared
264 by at least half of the trait pairs, including regions 9q34.2, 12q24.12, 12q24.31, and
265 19p13.2. We also observed mixed directions of allelic associations, with 6,721 top
266 SNPs (49.1%) consistently associated with specific traits, indicating that these
267 variants can either simultaneously reduce (3,185 SNPs) or increase (3,536 SNPs) the
268 number/percentage of BCTs and CVDs risks. In contrast, the remaining 50.9% of the
269 top SNPs showed opposite associations with specific traits, suggesting the presence of
270 different biological mechanisms.

271

272 For functional annotation, we utilized ANNOVAR and discovered that 8,201 (59.9%)
273 of the variants were intronic, 3,749 (27.4%) were intergenic, and 523 (3.8%) were
274 exonic. Among these, the index SNP rs1613662 at the 19q13.42 locus ($P_{PLACO} = 9.26$
275 $\times 10^{-10}$ for basophil count BASO-VTE and PLT-VTE) was related to an adipose
276 visceral omentum eQTL ($P_{Adipose_Visceral_Omentum} = 1.49 \times 10^{-5}$), encoding the collagen
277 receptor GPVI/FcR γ , primarily involving *GP6* variants (Supplementary Table 10).
278 This receptor interaction with subendothelial collagen exposed after vessel wall injury
279 can promote platelet activation and aggregation, thus affecting the risk of VTE²⁷.
280 Additionally, combined annotation-dependent depletion (CADD) scores revealed that
281 1,031 SNPs had scores greater than 12.37, with rs116843064 in the 19p13.2 region
282 having the highest CADD score of 33. A total of 484 top SNPs were found to

283 potentially affect transcription factor binding and correlate with gene target
284 expression. Among these, six SNPs, including rs4987082, rs12440045, rs6511703,
285 rs1214761, rs9810512, and rs6882088, had the highest credibility for regulatory
286 functions (RegulomeDB score: 1a). We further performed colocalization analysis on
287 13,697 potential pleiotropic loci, of which 1,709 (12.5%) showed strong
288 colocalization evidence (PPH4 > 0.7). Notably, the 12q24.31 locus affected 46 trait
289 pairs, with PPH4 values ranging from 0.740 to 0.995, demonstrating significant
290 pleiotropy.

291

292 **Candidate pleiotropic genes by position mapping**

293 We further integrated these pleiotropic SNPs to the gene level using multi-marker
294 analysis of genomic annotation (MAGMA) and identified 10,106 significant
295 pleiotropic genes (1,973 unique genes) ($P < 1.63 \times 10^{-8}$) (Fig. 3, Supplementary Table
296 12). Notably, 1,453 (73.6%) of these genes were widely shared between two or more
297 trait pairs. For example, *ATXN2*, *ACAD10*, *ALDH2*, *CUX2*, *BRAP*, *SH2B3*, and
298 *MAPKAPK5* were identified as significant pleiotropic genes in 69, 67, 64, 61, 58, 58
299 and 56 trait pairs, respectively. These genes are located in the 12q24.11-12q24.13
300 region, known for its pleiotropic effects on PCT and various cardiometabolic traits,
301 including fasting glucose, blood pressure, and obesity-related traits (body mass index
302 (BMI) and waist-to-hip ratio (WHR)). Depleting the cytoplasmic protein encoded by
303 *ATXN2* has resulted in defective platelet aggregation and dysregulation of hemostatic
304 processes²⁸. Additionally, polymorphisms in *ATXN2* significantly affect the
305 kynurenine level in erythrocytes²⁹ and are critical loci for systolic (SBP) and diastolic
306 blood pressure (DBP), as well as mean arterial pressure (MAP)³⁰. Consequently,
307 *ATXN2* plays a pivotal role in the onset of various CVD events by regulating blood
308 pressure. To ensure the robustness of our findings, SNPs were positionally remapped
309 using the SNP2GENE function of FUMA, which verified 88.5% of the genes
310 identified by MAGMA (Supplementary Table 10). Further comparisons of the
311 PLACO-based MAGMA results with single trait GWAS data for BCTs and CVDs

312 revealed 855 (8.5%) novel genes for BCTs, 4,938 (48.9%) novel genes for CVDs, and
313 229 genes that overlapped between BCTs and CVDs (Supplementary Table 12).

314

315 **Candidate tissue-specific pleiotropic genes by eQTL mapping**

316 To elucidate how the above SNPs affect gene expression in a tissue-specific manner,
317 we first used LDSC-specific expression (LDSC-SEG) to determine the tissue
318 association corresponding to each trait. We found that BCTs-related traits were mainly
319 significantly enriched in Adipose_Visceral_(Omentum), Cells_EBV-
320 transformed_lymphocytes, Lung, Small_Intestine_Terminal_Ileum and Whole_Blood
321 tissues (FDR < 0.05) (Supplementary Fig. 4, Supplementary Table 15A). In CVDs,
322 AF showed significant enrichment in heart-related tissues (Heart_Atrial_Appendage
323 and Heart_Left_Ventricle), while CAD showed considerable enrichment in
324 artery-related tissues (Artery_Aorta, Artery_Coronary, and Artery_Tibial). Subsequent
325 LDSC-SEG chromatin analysis showed that BCTs were mostly significantly enriched
326 in primary cells from peripheral blood (Supplementary Table 15B). In CVDs, AF was
327 mainly enriched in the fetal heart, and CAD was significantly enriched in the aorta
328 and coronary artery, confirming the multi-tissue gene expression results.

329

330 To overcome the limitation of the MAGMA approach (assigning SNPs to the nearest
331 gene without considering functional association), we employed eQTL Multi-marker
332 Analysis of GenoMic Annotation (eMAGMA) to link tissue-specific cis-eQTL
333 information to genes to generate more biologically meaningful results (Supplementary
334 Table 16). From an analysis of 10 selected tissues, we identified 2,328 unique
335 pleiotropic genes achieving Bonferroni-corrected significance, each highly enriched
336 in at least one specific tissue. Notably, 1,875 of these genes (80.5%) were present in
337 two or more trait pairs. Among them, genes such as *ABO* (n=125), *TMEM116* (n=99),
338 *ALDH2* (n=95), and *MAPKAPK5* (n=87) appeared in over half of the trait pairings,
339 each demonstrating specific tissue enrichments. In particular, the *ABO* gene is
340 predominantly found in liver and visceral adipose tissues; *TMEM116* in the artery
341 tibial and visceral adipose tissues; *ALDH2* in both artery tibial and artery aorta tissues;

342 and *MAPKAPK5* in adipose subcutaneous and visceral adipose tissues. Notably, the
343 *ABO* gene affects the serum levels of von Willebrand factor (vWF) and soluble
344 E-selectin³¹, which are involved in thrombosis and endothelial dysfunction,
345 respectively, and are critical for the development of cerebrovascular injury and
346 atherosclerosis^{31,32,33,34}. We further used the single-trait GWAS results to conduct
347 transcriptome-wide association study (TWAS) to identify tissue-specific pleiotropic
348 genes for complex traits and found 5,609 novel genes for BCTs and 20 novel genes
349 for CVDs (Supplementary Table 17). Notably, genes such as *ABO* and *ALDH2* were
350 identified in more than half of the trait pairs, and both eQTL-based strategies
351 highlighted that *ALDH2* in the 12q24.12 region was associated with a common
352 molecular mechanism for BCTs and CVDs, which may mediate CVDs
353 pathophysiology by affecting the metabolism of reactive aldehydes under oxidative
354 stress. However, the exact role of *ALDH2* in the blood phenotype remains to be
355 elucidated. In addition, we further validated 81.7% of the genes identified by
356 eMAGMA using eQTL mapping using FUMA (Supplementary Table 10).

357

358 In our study, MAGMA and eMAGMA analyses identified 5,063 pleiotropic genes, of
359 which 936 (313 unique) exhibited strong evidence of colocalization and were
360 included in subsequent analyses (Supplementary Table 8 and Supplementary Table
361 12). Notably, 194 of these genes demonstrated pleiotropic effects across two or more
362 BCT-CVD trait pairs, including significant genes such as *ALDH2*, *PHETA1*, and
363 *MAPKAPK5* (all located at 12q24.12), *CCDC92* (12q24.31), and *ZNF664* (12q24.31).
364 Interestingly, the degree of pleiotropy varied significantly among some genes across
365 different categories of trait pairs. For instance, of the 18 trait pairs associated with
366 *ACAD10*, 15 involved Leukocyte-CVD pairs, while the remaining 3 were
367 Erythrocyte-CVD. Similarly, *CCDC92* appeared in 20 trait pairs, with 15 categorized
368 as Erythrocyte-CVD, accounting for 17.9% of the total Erythrocyte-CVD. Conversely,
369 *CCDC92* featured less frequently in Leukocyte-CVD (4 pairs, representing 6.1% of
370 all such pairs) and Platelet-CVD (only 1 pair, or 4.2% of these pairings).

371

372 Therefore, considering that the association of genes with CVDs may be influenced by
373 BCT type, we categorized all BCTs-CVDs trait pairs into three groups based on BCT
374 types, including Leukocytes-CVDs, Platelets-CVDs, and Erythrocytes-CVDs, with
375 pleiotropic gene counts of 174, 117, and 164, respectively. Among the
376 Leukocytes-CVDs trait pairs, *ACAD10*, one of the specific genes, is not associated
377 with Leukocytes-AF. *ACAD10* is critical in mitochondrial fatty acid β -oxidation,
378 influencing leukocyte functions such as proliferation, cytokine production, and
379 adhesion molecule production. It is also an essential energy source for
380 cardiomyocytes, underscoring its significant role in CVD pathophysiology³⁵. Among
381 the Platelets-CVDs pairs, *TNFSF12* (*TWEAK*) was notably associated with PCT and
382 AF. The interaction of *TNFSF12* with the fibroblast growth factor-inducible molecule
383 14 (Fn14) activates signaling pathways essential for vascular and cardiac remodeling,
384 pivotal in acute and chronic CVDs³⁶. Furthermore, studies have linked serum *TWEAK*
385 levels to PLT, highlighting clinical relevance^{33,37}. For the Erythrocytes-CVDs pairs,
386 *CCDC92* was the most frequently pleiotropic gene, which affects the occurrence of
387 cardiovascular events by regulating adipose tissue distribution and insulin sensitivity,
388 highlighting its broad impact on metabolic and cardiovascular health^{38,39}.

389

390 **Potential shared biological mechanism between BCTs and CVDs**

391 We performed MAGMA gene set analysis to explore specific biological pathways or
392 cellular functions implicated in the BCTs-CVDs pair's genetic etiology. A total of
393 1,599 pathways were significantly enriched after Bonferroni correction ($P < 3.00 \times$
394 10^{-8}), including 169 Gene Ontology Biological Process (GO BP) terms, 30 KEGG
395 pathways, and 33 Reactome pathways (Supplementary Table 18). Since most genes
396 have obvious trait specificity and participate in different biological pathways, we still
397 divide the pathways enriched by BCTs-CVDs into three categories to observe whether
398 they have specific and reliable results. Of these, 992 were associated with the
399 Leukocytes-CVDs pairs, and more than half of these involved pathways were related
400 to the regulation of immune system processes, immune responses, and cellular

401 activation, affecting all leukocyte phenotypes except basophil-related parameters. In
402 contrast, the Platelets-CVDs pairs were enriched for only 77 pathways, mainly related
403 to hemostasis and platelet activation, signaling, and aggregation. VTE showed strong
404 correlations with all four platelet parameters in these specific pathways. For the
405 Erythrocytes-CVDs pairs, 530 pathways were enriched, mainly involving vascular
406 and circulatory system development, with AF and CAD being more highly associated
407 with these terms than other CVDs.

408

409 Further enrichment analysis of overlapping genes in MAGMA and eMAGMA
410 analyses using Metascape confirmed that the Leukocytes-CVDs related gene set was
411 mainly involved in the inflammatory response, the Platelets-CVDs related gene set
412 focused on platelet activation and aggregation, and the Erythrocytes-CVDs related
413 gene set was mainly engaged in the regulation of hematopoietic progenitor
414 differentiation, which is highly consistent with the results of the MAGMA gene set
415 analysis(Supplementary Table 19). These findings revealed the common molecular
416 genetic mechanisms behind the extensive multi-gene overlap between the three types
417 of BCTs and CVDs, highlighting important pathways that may become therapeutic
418 targets for treating these diseases.

419

420 **Identification of pathogenic proteins and drugs in cross-sectional traits**

421 To investigate the associations between plasma protein expression and disease risk,
422 we employed summary-data-based Mendelian Randomization (SMR). We sourced
423 blood cis-pQTL data from the UK Biobank Pharmaceutical Proteomics Project
424 (UKB-PPP) and the deCODE Health study. After excluding entries that failed the
425 heterogeneity in dependent instruments (HEIDI) test, underwent multiple SNP-SMR
426 sensitivity analyses, and surpassed the Bonferroni correction threshold, we identified
427 1,589 causal proteins, of which 1,534 were associated with BCTs and 55 with CVDs.
428 Among these, 49, 62, and 101 overlapping proteins were associated with leukocytes,
429 platelets, and erythrocytes, respectively, from deCODE Health and UKB-PPP studies,
430 with an additional eight proteins linked to CVDs. Remarkably, our analysis uncovered

431 only three pleiotropic proteins across seven distinct trait pairs, specifically SERPINE2
432 and TNFSF12 in Platelets-CVDs pairs and GP6 in both Platelets-CVDs and
433 Erythrocytes-CVDs pairs. Subsequent colocalization analysis confirmed that the GP6
434 gene polymorphic variant rs892090 demonstrated strong colocalization in all pertinent
435 trait pairs except MPV-VTE (Supplementary Table 20).

436

437 **Discussion**

438 We discovered significant genetic overlaps between BCTs and CVDs through
439 comprehensive pleiotropic analyses of large-scale GWAS summary statistics.
440 However, evidence for a direct causal relationship remains limited. Our studies
441 identified 571,782 pleiotropic variants and 313 unique pleiotropic genes, which show
442 varied CVD risks across different BCT subgroups, including leukocytes, platelets, and
443 erythrocytes. We further explored the distinct characteristics of these blood cell
444 phenotypes, revealing that specific pathways play key roles in their pathophysiology.
445 For platelet-CVD subgroups, platelet activation is central; for erythrocyte-CVD
446 subgroups, the regulation of hematopoietic progenitor differentiation is crucial; and
447 for leukocyte-CVD subgroups, the inflammatory response is pivotal. Additionally, our
448 research has identified GP6, TNFSF12, and SERPINE2 as potential therapeutic
449 targets for these conditions. These findings underscore the value of BCT parameters
450 as biomarkers for assessing CVD risk and provide valuable insights into the genetic
451 underpinnings of these associations.

452

453 We identified a substantial genetic overlap between BCTs and CVDs using diverse
454 analytical methodologies, including LDSC, GPA, and LAVA. Our analysis indicated
455 significant genome-wide genetic correlations for 8.6% of trait pairs, corroborating
456 previous phenotypic associations and confirming a shared genetic foundation.
457 Although genome-wide r_g (averaging shared SNP effects across the genome) may
458 obscure specific genetic associations within genomic regions, we utilized LAVA to
459 pinpoint multiple specific genomic areas. We observed local- r_g s for all trait pairs
460 within these regions, indicating confounding effects that are not evident in

461 genome-wide estimates. For instance, despite a genome-wide r_g near zero according
462 to LDSC, both BASO_P-AF and BASO-CAD demonstrated approximately equal
463 numbers of positively and negatively correlated genetic regions. This nuance
464 underscores significant genetic correlations that broader statistical frameworks might
465 overlook. Our GPA analysis further confirmed substantial polygenic overlap among
466 all trait pairs, highlighting the complex genetic interplay between BCTs and CVDs. In
467 conclusion, our study reveals an extensive shared genetic liability between BCTs and
468 CVDs, suggesting that their relationships are more robust and intricate than
469 previously recognized.

470

471 The LHC-MR method explored the causal relationship at the level of vertical
472 pleiotropy, which can reveal part of the common genetic mechanisms between BCTs
473 and CVDs. We identified 23 putative causal relationships, especially positive ones in
474 RDW_CV-VTE, Stroke-eosinophil count (EO), and Stroke-PCT, consistent with
475 previous studies^{20,40}. The causal link for RDW_CV-VTE may be the reduced
476 deformability and increased aggregation of red blood cells, elevating viscosity and
477 impeding blood flow, thereby increasing VTE risk. Conversely, our findings did not
478 confirm the previously reported associations between high neut and increased risks of
479 AF, HF, PAD, and Stroke, as suggested by Jiao *et al*⁴¹. This discrepancy could stem
480 from the significant sample overlap between BCTs and CVDs GWAS samples in the
481 UK Biobank, a typical challenge in two-sample Mendelian randomization analyses.
482 Our LHC-MR approach addressed and mitigated genetic confounding due to this
483 sample overlap and clarified the exposure-outcome relationships. Additionally, we
484 report for the first time a positive association between HF and several BCTs, such as
485 MPV, MSCV, PCT, and PLT, and a negative association with HCT. However, the
486 negative relationship between AF and PLT is consistent with previous studies.
487 Specifically, a meta-analysis by Alexander *et al.* indicated a significant reduction in
488 PLT in AF patients, potentially influenced by factors such as AF type, smoking status,
489 and geographic region⁴². We found no causal associations between the remaining trait
490 pairs, and the limited causal evidence suggests that the BCTs-CVDs trait pair

491 associations are less driven by causality and may be primarily mediated by horizontal
492 pleiotropy.

493

494 Although we discovered that BCTs and CVDs share a common genetic foundation, it
495 remains unclear whether the association between them occurs via horizontal or
496 vertical pleiotropy. We first investigated the horizontal pleiotropy level and identified
497 multiple pleiotropic loci associated with BCTs and CVDs, among which important
498 loci such as 9q34.2, 12q24.31, and 12q24.12 affected more than 50% of the trait pairs.
499 Recent research has underscored the pleiotropic effects of genes within the 12q24.12
500 region on CVDs⁴³. Notably, the gene *ALDH2*, encoding aldehyde dehydrogenase 2, is
501 associated with CAD, blood pressure regulation, and alcohol-induced cardiac
502 dysfunction⁴⁴. This enzyme is essential for metabolizing both endogenous and
503 exogenous aldehydes; its dysfunction leads to aldehyde accumulation, markedly
504 increasing the risk of specific CVDs. Furthermore, *ALDH2* modulates
505 atherosclerosis-related risk factors such as foam cell formation and macrophage
506 effervescence through non-enzymatic pathways⁴⁵. Another critical gene in this region,
507 *SH2B3* (also known as lymphocyte adaptor protein or *LNK*), regulates cytokine
508 signaling and cell proliferation⁴⁶. In mouse models, targeted deletion of *LNK* disrupts
509 the negative feedback regulation of various pathways, affecting hematopoiesis and
510 enhancing thrombopoietin (TPO) signaling⁴⁷. This disruption leads to increased
511 thrombosis and atherosclerosis, thereby elevating the incidence of CVD events.
512 Consistently, studies have linked the *LNK* rs3184504 (T allele, *R262W*) variant with
513 an increased risk of CAD and thrombotic stroke⁴⁸. HyPrColoc results confirm that
514 rs3184504 is a common pathogenic variant across CAD, VTE, and 19 other BCTs,
515 highlighting the pleiotropic role of *SH2B3*. The gene *MAPKAPK5*, which encodes the
516 MK5 protein—a serine/threonine kinase—also shows high expression levels in the
517 human heart⁴⁹. MK5 plays a role in endothelial cell migration and angiogenesis⁵⁰ and
518 influences erythrocytes' structure, metabolism, and ion channels⁵¹, thus affecting
519 susceptibility to atherosclerosis⁵². In conclusion, the identified pleiotropic loci

520 associated with BCTs and CVDs reveal a strong genetic interrelation between these
521 traits, providing deeper insights into their complex genetic associations.

522

523 In our study, we employed two gene mapping strategies to associate candidate SNPs
524 with genes that influence both BCTs and CVDs. Specifically, among the
525 Leukocytes-CVDs trait pairs, *ALDH2*, *MAPKAPK5*, and *ACAD10*, all located at
526 12q24.12, were identified as significant pleiotropic genes. *ACAD10*, in particular,
527 plays a crucial role in activating mitochondrial fatty acid oxidation (FAO)⁵³, which is
528 pivotal in developing atherosclerosis through *NLRP3* inflammasome activation and
529 IL-4-induced macrophage polarization⁵⁴. Notably, the FAO inhibitor trimetazidine
530 effectively prevents foam cell formation from macrophages originating from
531 circulating monocytes in the arterial intima⁵⁵. About Platelets-CVDs trait pairs,
532 *TNFSF12* (17p13.1) has emerged as key pleiotropic genes. SMR studies have
533 demonstrated a significant association between *TNFSF12* protein levels and PCT-AF.
534 *TNFSF12*, also known as *TWEAK*, activates the JAK2/STAT3 pathway via the Fn14
535 receptor, inducing hypertrophy in HL-1 atrial myocytes—a vital adaptive change in
536 AF development⁵⁶. This pathway also influences PLT and vascular permeability³³.
537 Given their potential, the drugs BIIB-023 and RO-5458640, currently indicated for
538 lupus nephritis and rheumatoid arthritis, respectively, warrant further investigation in
539 clinical trials to evaluate their efficacy in treating PCT and AF. Regarding
540 Erythrocytes-CVDs trait pairs, *ZNF664* and *CCDC92*, both located in the 12q24.31
541 region, are critical. *CCDC92*, a coiled-coil domain protein, is intimately associated
542 with lipid metabolism and insulin sensitivity³⁸. Insulin resistance, influenced by
543 *CCDC92*, leads to coronary endothelial dysfunction and promotes vascular smooth
544 muscle cell proliferation via insulin-like growth factor receptors, exacerbating
545 atherosclerosis⁵⁷. At the same time, no studies have directly linked *CCDC92* with
546 erythroid characteristics; *ZNF664* and *CCDC92* exhibit co-regulated expression
547 patterns and engage in nearly identical molecular pathways^{58,59}.

548

549 Shared genetic determinants indicate common biological pathways underlying

550 Leukocytes-CVDs trait pairs. Our pathway analysis revealed that inflammatory
551 responses are critical, with *TNFSF12* playing a significant role. Specifically,
552 inflammatory reactions within the vessel wall, coupled with oxidative stress from
553 endothelial dysfunction, are pivotal in the progression of atherosclerosis⁶⁰. For
554 example, circulating monocytes infiltrate fatty streaks and differentiate into
555 macrophages with pro-inflammatory properties⁶¹. These macrophages then recruit
556 inflammatory factors, amplifying local inflammatory responses. A notable mediator,
557 *Irg1*, exacerbates inflammation by promoting the formation of neutrophil extracellular
558 traps (NETs) and activating the *NLRP3* inflammasome in macrophages, enhancing
559 IL-1 β release⁶². In analyzing Platelets-CVDs trait pairs, we focused on key processes
560 such as hemostasis, platelets activation, and aggregation involving *GP6*. Platelets,
561 derived from megakaryocytes, are fundamental to the pathogenesis of coronary
562 thrombosis and atherosclerosis⁶³. Peptide hormone receptors on platelets may trigger
563 thrombosis⁶⁴, while the chemokines they secrete play roles in both inflammation and
564 hemostasis⁶⁵. Additionally, oxidative stress and the production of reactive oxygen
565 species (ROS) activate platelets, profoundly affecting CVD pathogenesis, especially
566 in older individuals. Regarding Erythrocytes-CVDs trait pairs, pathways involved in
567 vascular development and the circulatory system are crucial, with *TNFSF12* also
568 implicated. Erythrocytes primarily influence blood viscosity, impacting the friction
569 exerted on the arterial wall, a key factor in maintaining systemic arterial pressure
570 post-birth and promoting vasoconstriction⁵. Pathologically, collisions of erythrocytes
571 with the arterial wall can lead to local retention and hemolysis of their membrane
572 lipids, which are associated with both the early and late stages of atherosclerosis^{66,67}.
573 From a classification perspective, our study elucidates how different pathways
574 mediate the association between BCTs and CVDs, highlighting that targeted
575 regulation of key genes could significantly reduce disease risk.

576

577 Using SMR and colocalization analysis, we identified three significantly shared
578 proteins—GP6, TNFSF12, and SERPINE2—across seven trait pairs. Both GP6 and
579 TNFSF12 are key target proteins currently under clinical investigation. GP6 encodes

580 platelets glycoprotein VI, essential for collagen-dependent activation, signal
581 transduction, and full platelets activation, adhesion, and aggregation⁶⁸. Variants in
582 GP6, such as the common variant rs1613662, are associated with increased VTE risk
583 and alterations in platelets function, impacting CVDs susceptibility. Although no
584 studies have reported how GP6 participates in erythrocyte physiological processes,
585 our analysis highlights that GP6 upregulation correlates with heightened VTE risk and
586 elevations in 2 platelet parameters (MPV and PDW) and 4 erythrocyte parameters
587 (HLR_P, HLR, RET_P, and RET). This suggests that the GP6 inhibitor, glenisomab,
588 may represent a promising drug repurposing opportunity to mitigate excessive VTE
589 risk and elevated platelet and erythrocyte parameters. Restingly, common CVD
590 preventive drugs such as aspirin do not target the pathogenic proteins identified in our
591 SMR analysis. This may be due to the inability of blood-based cis-eQTL analysis to
592 capture anticoagulant factors produced by the liver. Moreover, the TNFSF12 inhibitor
593 BIIB-023 could be repurposed to reduce the risk of PCT and AF complications.
594 However, the underlying mechanisms remain under-explored, highlighting our
595 proposal as novel and underscoring the need for further research.

596

597 In conclusion, this is the first study to characterize the pleiotropic effects of a range of
598 BCTs and CVDs on a large scale and provide important insights into the genetic
599 architecture widely distributed throughout the genome and the mechanisms behind
600 common genetic diseases. These results have successively provided new clues at the
601 level of pleiotropic SNPs and genes, biological pathways, potential drug proteins, and
602 causal relationships and will facilitate further laboratory investigations and clinical
603 studies.

604

605 **Limitations of the study**

606 Our study presents several limitations. First, the GWAS datasets employed to
607 investigate BCTs and CVDs may include cases with concurrent blood cell
608 abnormalities and CVDs, potentially introducing bias into our analysis of genetic
609 overlap. Second, the lack of rare variants in most GWAS datasets restricts our ability

610 to explore pleiotropy between rare loci associated with BCTs and CVDs, which could
611 deepen our understanding of the disease mechanisms. Third, while minimizing
612 demographic bias, our focus on European populations limits our findings'
613 generalizability to other ethnic groups. Finally, the new pathway signals and gene loci
614 identified require further validation through clinical cohort studies or animal models
615 to bolster the robustness and credibility of our results.

616

617 **STAR★Methods**

618 **Key resources table**

REAGENT or RESOURCE	IDENTIFIER
Deposited data	
Blood cell traits	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKB B_blood_cell_traits/
Atrial fibrillation	https://www.ebi.ac.uk/gwas/studies/GCST006414
Coronary artery disease	https://cvd.hugeamp.org/datasets.html
Venous thromboembolism	https://www.decode.com/summarydata/
Heart failure	https://www.ebi.ac.uk/gwas/studies/GCST009541
Peripheral artery disease	https://cvd.hugeamp.org/datasets.html
Stroke	https://www.ebi.ac.uk/gwas/studies/GCST90104539
Software and algorithms	
LDSC (v1.0.1)	https://github.com/bulik/ldsc
MiXeR (v1.3)	https://github.com/precimed/mixer
LAVA (v0.1.0)	https://github.com/josefin-werme/LAVA
LHC-MR (v0.0.0.9000)	https://github.com/LizaDarrous/lhcMR
PLACO (v0.1.1)	https://github.com/RayDebashree/PLACO
FUMA (v1.5.4)	http://fuma.ctglab.nl/
HyPrColoc(v1.0)	https://github.com/jrs95/hyprcoloc
MAGMA (v.1.08)	https://ctg.cncr.nl/software/magma
e-MAGMA	https://github.com/eskederks/eMAGMA-tutorial
TWAS	http://gusevlab.org/projects/fusion/
SMR (v1.31)	https://yanglab.westlake.edu.cn/software/smr/
COLOC (v5.2.1)	https://github.com/chr1swallace/coloc
R (v.4.1.3)	https://www.r-project.org/

619

620 **Resource availability**

621 **Lead contact**

622 Further information and requests for resources and reagents should be directed to and
623 will be fulfilled by the lead contact, Luke Kong (kongluke2005@163.com).

624

625 **Materials availability**

626 This study did not generate new unique reagents.

627

628 **Data and code availability**

629 The study used only openly available GWAS summary statistics on blood cell traits
630 and cardiovascular diseases that have originally been conducted using human data.

631 GWAS summary statistics on BCTs are available at

632 ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_trait

633 s/. GWAS summary statistics on AF, HF, and Stroke are available at the GWAS

634 Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary

635 statistics on CAD and PAD are publicly available for download at the Cardiovascular

636 Disease Knowledge Portal (CVDKP) website: <https://cvd.hugeamp.org/datasets.html>.

637 GWAS summary statistics on VTE are obtained from the deCODE genetics website:

638 <https://www.decode.com/summarydata/>. All data are publicly available and listed in

639 the key resources table. No unique datasets or code were generated for this study. Any

640 additional information required for reanalysis of the data reported in this article is

641 available from the primary contact on request.

642

643 **Method details**

644 **Study Design**

645 Figure 1 presents the workflow for this study

646

647 **Data selection and quality control**

648 Summary statistics for 29 BCTs were retrieved from a genome-wide association study
649 of 408,112 participants of European ancestry in the UK Biobank cohort, which
650 included data on leukocytes, platelets, and erythrocytes¹⁶. Additionally, we integrated
651 GWAS summary data on six major CVDs for individuals of European ancestry with
652 sample sizes exceeding 50,000 to ensure robust statistical power. Specifically,
653 summary data for AF were derived from a large-scale meta-analysis including six
654 contributing studies: the Nord-Trøndelag Health Study (HUNT), deCODE, the
655 Michigan Genomics Initiative (MGI), DiscovEHR, UK Biobank, and the AFGen
656 Consortium, encompassed 60,620 cases and 970,216 controls of European ancestry⁶⁹.
657 Summary data for CAD were derived from GWAS summary statistics from a
658 genome-wide meta-analysis by the CARDIoGRAMplusC4D Consortium and UK
659 Biobank, including 181,522 cases and 984,168 controls of European ancestry⁷⁰.
660 Summary data for VTE were sourced from a genome-wide association study by Jonas
661 Chouse et al., featuring 81,190 cases and 1,419,671 controls of European ancestry⁷¹.
662 Summary statistics for HF were extracted from a GWAS meta-analysis by Sonia Shah
663 et al., including data from 47,309 cases and 930,014 controls of European ancestry
664 across 26 studies from the Heart Failure Molecular Epidemiology for Therapeutic
665 Targets (HERMES) Consortium⁷². Summary statistics for PAD were obtained from a
666 large-scale GWAS meta-analysis comprising 12,086 cases and 499,548 controls of
667 European ancestry⁷³. Summary statistics for stroke, involving 73,652 cases and
668 1,234,808 controls of European ancestry, were retrieved from the GIGASTROKE
669 consortium⁷⁴. Detailed information on these GWAS summary statistics and their
670 original publication sources is available in Table 1.

671

672 We implemented stringent quality control measures to ensure the integrity of our
673 GWAS summary data and facilitate a valid comparison between BCTs and CVDs.
674 These included (i) aligning the data with the hg19 genome build based on the 1000
675 Genomes Project v3 Europeans reference; (ii) filtering out SNPs that either lacked a
676 reference SNP ID (rsID) or had duplicated rsIDs; (iii) excluding non-biallelic SNPs,
677 which do not have precisely two allele forms; (iv) removing SNPs with a minor allele

678 frequency (MAF) below 0.01, ensuring that only commonly occurring variants are
679 analyzed. Following these measures, we included only common SNPs in the analysis,
680 totaling 6,923,169, available across all traits.

681

682 **Statistical Analysis**

683 **Genome-wide genetic correlations between BCTs and CVDs**

684 We used LDSC to analyze the h^2_{SNP} and r_g between 29 BCTs and 6 major CVDs.
685 LDSC helps quantify the contributions of polygenic effects by examining the
686 relationship between linkage disequilibrium scores from GWAS summary results and
687 SNP test statistics⁷⁵. Initially, univariate LDSC was used to assess the SNP-based
688 heritability for each of the 29 BCTs and 6 CVDs, which measures the proportion of
689 phenotypic variance explained by common genetic variants. For this analysis, we
690 calculated LD scores using the 1000 Genomes Phase 3 European reference⁷⁶,
691 excluding variants within the major histocompatibility complex (MHC) region (CHR
692 6: 25–35 Mb) due to its complex LD structure. We then conducted bivariate LDSC to
693 evaluate the genetic correlations among 174 BCTs and CVDs pairwise combinations.
694 This step calculates the proportion of SNP-based heritability shared between two
695 traits, normalized by the geometric mean of their heritability estimates, with
696 correlation values ranging from -1 to +1 to indicate the direction of genetic effects. To
697 adjust for multiple comparisons, we employed the FDR method, setting an FDR
698 threshold of <0.05 to determine statistical significance.

699

700 We employed LDSC-SEG to explore whether the SNP heritability of 29 BCTs and 6
701 major CVDs is significantly correlated with tissue-specific gene expression, thereby
702 identifying relevant tissues⁷⁷. Utilizing multi-tissue gene expression data from the
703 Genotype-Tissue Expression (GTEx) project and additional data from the Franke
704 laboratory, we analyzed patterns across 53 tissues and 152 cell types⁷⁸. Furthermore,
705 we enhanced our validation process by incorporating chromatin-based annotations
706 linked to six epigenetic marks: DNase hypersensitivity, H3K27ac, H3K4me1,
707 H3K4me3, H3K9ac, and H3K36me3. These annotations included 93 tags from the

708 Encyclopedia of DNA Elements (ENCODE) project and 396 tags from the Roadmap
709 Epigenomics database, which validated our analysis. To determine the statistical
710 significance of the coefficients for the identified tissues, we applied a FDR threshold
711 of 0.05.

712

713 **Local genetic correlation analyses between BCTs and CVDs**

714 To investigate local genetic correlations between 29 BCTs and 6 major CVDs within
715 specific genomic regions, we utilized the LAVA. LAVA computed local- r_g s for 2,495
716 semi-independent genetic loci, each approximately 1 Mb in size, identified by
717 dividing the genome into blocks with minimal LD between them. The LD reference
718 panel, derived from the 1000 Genomes Project Phase 3 of European ancestry⁷⁶,
719 excluded the MHC region (chr6:25-35 Mb). Initial univariate tests ascertained the
720 local heritability of each trait using a stringent p-value threshold of $< 1 \times 10^{-4}$ to
721 exclude loci with insignificant genetic correlation or univariate heritability.
722 Subsequently, we performed 80,126 bivariate tests on loci and traits that exhibited
723 significant univariate genetic signals. To address the conservative nature of the
724 Bonferroni correction, we applied a FDR of 0.05 to identify significant associations.

725

726 For regions identified by LAVA with evidence of shared risk loci across multiple
727 phenotypes, we conducted a multi-trait co-localization analysis using HyPrColoc⁷⁹.
728 This method builds on the COLOC framework and simultaneously assesses
729 co-localization among several traits by calculating the PP of multiple traits
730 co-localizing due to a single causal variant. A SNP with a PP exceeding 0.7 indicates a
731 significant co-localization signal, pointing to shared causal mechanisms within the
732 region.

733

734 **Genetic overlap analysis between BCTs and CVDs**

735 To further explore the genetic overlap between BCTs and six major CVDs, we
736 applied the GPA⁸⁰. This method leverages GWAS summary results, using the
737 intersection of P-values for each phenotype as input, and fits a GPA model based on

738 the resulting P-value matrix data. GPA categorizes SNPs into four groups according
739 to their association with the traits: SNPs unrelated to any traits (π_{00}), related only to
740 the first trait (π_{10}), related only to the second trait (π_{01}), and associated with both
741 traits (π_{11}). This classification helps estimate the proportions of SNPs and elucidates
742 the causal effects on the phenotypes. The statistical significance of the genetic overlap
743 is assessed using a Likelihood Ratio Test (LRT), which tests the fit of the four-group
744 model against a model of independent effects. GPA assumes P-values from null SNPs
745 follow a uniform distribution, while those from non-null SNPs follow a Beta
746 distribution. The PAR, defined as $\pi_{11}/(\pi_{01} + \pi_{10} + \pi_{11})$, represents the proportion of
747 SNPs associated with both traits relative to those associated with at least one trait⁸¹.
748 To minimize the influence of LD on our GPA estimates, we performed LD pruning
749 using PLINK⁸² with genotype data from the 1000 Genomes Project Phase 3 for
750 European ancestry, selecting relatively independent SNPs⁷⁶. We then applied the FDR
751 method to correct for multiple testing, with an FDR threshold of <0.05 to determine
752 statistical significance.

753

754 **Mendelian randomization analysis using LHC-MR**

755 We employed the LHC-MR method to explore potential causal relationships between
756 29 BCTs and 6 major CVDs⁸³. Unlike traditional polygenic MR approaches that rely
757 only on genome-wide significant SNPs, LHC-MR exploits all genome-wide variation
758 for causal estimation, using structural equation models to relate genome-wide
759 associations to traits and confounders. LHC-MR enhances the ability to estimate
760 bidirectional causal effects, direct heritability, and confounding effects, as well as
761 accommodate sample overlap. Moreover, we also applied traditional bidirectional MR
762 models for sensitivity analysis, including MR Egger, weighted median, inverse variance
763 weighted (IVW), simple mode, and weighted mode⁸⁴. Estimates from LHC-MR are
764 reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). We
765 applied a Bonferroni correction to rigorously evaluate causal relationships between
766 trait pairs, setting a significance threshold at $P < 1.44 \times 10^{-4}$ (0.05 divided by 174 pairs,
767 then divided by 2 to account for testing in both directions). A unidirectional causal

768 relationship was established when the P-value in one direction was below the
769 threshold, while in the opposite direction, it exceeded 0.05. Conversely, a
770 bidirectional relationship was confirmed when the P-values in both directions were
771 below 1.44×10^{-4} .

772

773 **SNP-level Analysis**

774 **Pleiotropic SNPs Identified by PLACO**

775 To assess the evidence for horizontal pleiotropy between 29 BCTs and 6 major CVDs,
776 we utilized the PLACO. PLACO is a sophisticated statistical method designed to
777 detect pleiotropic associations of each variant by evaluating the hypothesis that a SNP
778 is associated with neither or just one of the traits⁸⁵. This hypothesis is subdivided into
779 four specific scenarios: (1) H00, indicating no association with either trait; (2) H10,
780 suggesting an association exclusively with the first trait; (3) H01, indicating an
781 association solely with the second trait; and (4) H11, representing a pleiotropic
782 association with both traits. The test statistic is calculated as the product of the Z
783 statistics for the SNPs for each trait, which is assumed to follow a mixture distribution.
784 To ensure accuracy, SNPs with squared Z statistics (Z^2) greater than 100 are excluded
785 from analysis. SNPs are declared significantly pleiotropic at the genome-wide level if
786 their *P*-values are less than 5×10^{-8} .

787

788 **Genomic loci definition and functional analysis**

789 We employed the FUMA platform⁸⁶ to identify and functionally annotate independent
790 genomic loci and pleiotropic SNPs identified through PLACO. FUMA processes
791 GWAS summary statistics to annotate and prioritize SNPs and genes, enhancing data
792 interpretation through interactive visualizations⁷⁶. Using European population data
793 from the 1000 Genomes Phase 3 as a reference, we identified independently
794 significant SNPs ($P < 5 \times 10^{-8}$, $r^2 < 0.6$) from GWAS results. LeadSNPs were then
795 defined from these SNPs based on mutual independence ($r^2 < 0.1$), and genomic risk
796 sites were determined where SNPs were in LD ($r^2 > 0.6$). LD blocks within lead SNPs,
797 separated by less than 500 kb, were combined into single sites, with the top lead SNP

798 determined by the lowest P value in each site. We then evaluated the directional
799 effects of these top SNPs by comparing Z-scores, considering them novel if
800 inconsistent with any previously reported loci for BCTs or CVDs in original GWAS.
801 For functional and pathogenic prediction of variants, we utilized ANNOVAR,
802 applying metrics like the CADD score to predict the deleteriousness of variants based
803 on 67 functional annotations. SNPs with a CADD score over 12.37 were considered
804 harmful⁸⁷. The regulatory potential of SNPs was assessed using RegulomeDB scores,
805 ranging from 1a (strong evidence of regulatory function) to 7, with lower scores
806 indicating higher activity⁸⁸. Chromatin states, predicted by ChromHMM using five
807 chromatin markers across 127 epigenomes, helped highlight the regulatory landscape
808 of genomic regions⁸⁹. Lastly, SNP-gene associations were analyzed through positional
809 mapping within a 10 kb window of genes and eQTL mapping from GTEx v8 data to
810 identify significant cis-SNP gene pairs within 1 Mb relevant to the studied traits.

811

812 **Bayesian colocalization analysis**

813 Bayesian colocalization analysis used the 'coloc' R package on pleiotropic loci
814 annotated by FUMA to identify shared causal variants within each locus⁹⁰. This
815 analysis assesses whether specific loci contain a causal variation that influences two
816 traits simultaneously. We tested five hypotheses using COLOC to evaluate different
817 scenarios of genetic influence at these loci⁹¹: PP0: no association with either trait; PP1:
818 a causal variant affects only the first trait; PP2: a causal variant affects only the
819 second trait; PP3: different causal variants affect each trait.; PP4: a common causal
820 variant affects both traits. Loci with a posterior probability for hypothesis four (PP.H4)
821 greater than 0.7 were deemed to exhibit significant colocalization. Within these loci,
822 the SNP showing the highest PP.H4 was identified as the putative causal variant,
823 suggesting a strong genetic link between the traits at this genomic location.

824

825 **Gene-level Analysis**

826 **Gene-based association analysis using MAGMA**

827 To identify candidate pleiotropic genes based on the pleiotropic SNPs identified by
828 PLACO and single-trait GWAS results, we employed the MAGMA. This analysis
829 utilizes multiple linear principal component regression to map SNP annotations from
830 GWAS data onto the genome, detecting gene-disease associations. MAGMA's
831 strength lies in aggregating evidence from multiple genetic variants within the same
832 gene to enhance the detection of novel genetic signals. For analytical robustness, we
833 restricted our analysis to protein-coding genes containing at least ten SNPs. Gene
834 annotations were aligned with the Genome Reference Consortium Human Build 37
835 (hg19), and the analysis incorporated the 1000 Genomes Phase 3 European LD score
836 reference panel⁷⁶, focusing on 17,636 autosomal protein-coding genes. SNPs were
837 systematically assigned to genes based on their location within the gene body or
838 within a ± 10 kb window surrounding the gene. Additionally, regions within the MHC
839 (chr6:25-35 Mb) were excluded due to their complex linkage disequilibrium patterns.
840 We applied a rigorous Bonferroni correction for multiple testing across 17,636
841 protein-coding genes and 174 trait pairs, setting a stringent significance threshold for
842 the MAGMA analysis at $P < 0.05/(17,636 \times 174)$.

843

844 **Investigation of the tissue-specific genes using EMAGMA and TWAS**

845 To overcome limitations in identifying causal genes using traditional MAGMA,
846 which assigns SNPs to genes within a genomic window, we implemented
847 E-MAGMA⁹² for transcriptome-wide association analysis. This enhanced approach
848 uses tissue-specific cis-eQTL information from the GTEx v8 to link SNPs more
849 accurately with their putative genes, thereby improving the biological interpretability
850 of gene-based association analyses in BCTs and CVDs. E-MAGMA, adhering to the
851 statistical framework of MAGMA, utilizes multiple linear principal component
852 regression models. We focused our analysis on ten GTEx v8 tissues previously
853 identified as relevant to BCTs and CVDs, including arterial, adipose, and cardiac
854 tissues. To mitigate analytical complexities, regions like the MHC (chr6:25-35 Mb)
855 were excluded, and we employed Bonferroni-corrected significance thresholds
856 tailored per tissue and trait pair, ensuring robust statistical validation.

857

858 Complementing our E-MAGMA analysis, we conducted TWAS⁹³ using the
859 Functional Summary-based Imputation (FUSION) approach. TWAS integrates gene
860 expression data with single-trait GWAS results to uncover tissue-specific genetic
861 influences. We employed various prediction models, including Best Linear Unbiased
862 Prediction (BLUP), Least Absolute Shrinkage and Selection Operator (LASSO),
863 Elastic Net, and Bayesian Sparse Linear Mixed Model (BSLMM), selecting the model
864 that provided the best prediction accuracy for each tissue. Adjustments for multiple
865 comparisons were made using the Bonferroni method across each tissue type to
866 ensure the statistical rigor of our findings.

867

868 **Pathway-level analysis using MAGMA and Metascape**

869 We used MAGMA gene set analysis to elucidate the biological relevance of
870 pleiotropic genes identified from overlaps detected by MAGMA and subsequent
871 pathway enrichment annotation⁹⁴. This involved a competitive gene set enrichment
872 analysis using MAGMA, which assesses whether genes within specific sets exhibit
873 stronger associations with the phenotype than those in other gene sets across the
874 genome. Our analysis included 9,398 gene sets from the Molecular Signatures
875 Database (MSigDB, version 2023.1), particularly focusing on the C2: Reactome
876 Pathways and C5: GO Biological Processes and various biological process sets. We
877 applied a stringent Bonferroni correction for multiple testing, setting the threshold at
878 $P = 0.05 / (7744 + 186 + 1654) / 174 = 3.00 \times 10^{-8}$ to ensure robust statistical validity.

879

880 In addition, we used Metascape to perform pathway enrichment analysis on genes
881 significantly identified in MAGMA and E-MAGMA analyses to elucidate the
882 biological functions and pathways of pleiotropic genes associated with BCTs and
883 CVDs. Metascape⁹⁵ integrates functional enrichment analysis, interaction analysis,
884 gene annotation, and member search functions to facilitate comprehensive
885 bioinformatics analysis of bulk genes. For pathway enrichment analysis, we used the
886 following ontology sources: GO annotation, KEGG, and Reactome pathways. P

887 values below 0.01 were considered statistically significant.

888

889 **Proteome-wide Mendelian Randomization analysis using SMR and**

890 **Colocalization analysis**

891 To explore potential common pathogenic factors at the proteomic level between 29
892 BCTs and 6 major CVDs, we employed SMR⁹⁶. We analyzed disease GWAS data
893 and pQTL data from the deCODE Health study and the UKB-PPP. The deCODE
894 study measured 4,719 plasma proteins in 35,559 Icelandic individuals using the
895 SomaScan platform, while the UKB-PPP assessed 2,940 proteins in 34,557 European
896 individuals using the Olink Explore platform. Instrumental variables for SMR were
897 selected based on genome-wide significant SNPs ($P < 5 \times 10^{-8}$) located within ± 1 Mb
898 of the transcription initiation sites of target genes. SMR is a novel MR method used to
899 determine the association between genetically determined traits, such as gene
900 expression and plasma protein levels, and outcomes of interest, such as disease
901 phenotypes. This method integrates multi-omics data to facilitate the exploration of
902 potential causal relationships between specific drug targets and diseases. To validate
903 the observed causal associations, the HEIDI⁹⁶ test is applied; a p-value below 0.01
904 indicates the presence of linkage disequilibrium and pleiotropy. For sensitivity
905 analysis, SMR employs multi-SNP-SMR for each circulating protein, setting a
906 significance threshold at $p < 0.05$, strengthening the main analysis's evidence. The
907 significance level is adjusted for multiple testing using the Bonferroni method,
908 establishing the threshold at $p < 5.23 \times 10^{-7}$ (0.05 divided by 2,730 unique proteins
909 and 35 traits). We then performed Bayesian colocalization analysis to complement our
910 SMR findings and determine whether the same causal variants underlie the
911 associations between protein levels and disease phenotypes. A posterior probability
912 (PP.H4) greater than 0.7 indicates significant colocalization, suggesting that identical
913 genetic factors may influence protein abundance and disease outcomes concurrently.

914

915 To assess the therapeutic potential of the identified proteins, we utilized the
916 OpenTargets database, which compiles comprehensive data from 22 renowned

917 sources. These sources include genetic associations, somatic mutations, existing drugs,
918 differential expression, animal models, and insights into pathways and systems
919 biology, providing a rich foundation for identifying potential therapeutic applications.
920 The database further enhances our analysis by categorizing protein-related drugs
921 according to their clinical trial phases, as reported on the ClinicalTrials website.
922 Additionally, to ensure the reliability of our findings, we cross-referenced the
923 identified proteins against a well-curated list of druggable genes. Finally, we
924 thoroughly examined the drugs associated with these target proteins, assessing their
925 relevance and potential efficacy based on current clinical and preclinical evidence.

926

927

928 **Declaration of interests**

929 The authors declare no competing interests.

930

931 **Acknowledgements**

932 Not applicable.

933

934 **Author contributions**

935 L.K., F.L., B.Z. and Y.L. conceptualized and supervised this project and wrote the
936 manuscript. L.K. and K.Y. performed the main analyses and wrote the manuscript.

937 L.K., L.Z., Y.Z., M.C., and Z.H. performed the statistical analysis and assisted with
938 interpreting the results. Q.W. and Q.F. provided expertise in cardiovascular biology
939 and GWAS summary statistics. All authors provided intellectual content and approved
940 the final version of the manuscript.

941

942 **References**

- 943 1. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA,
944 Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. *N Engl J Med*.
945 2015;372(14):1333-41. doi:10.1056/NEJMoa1406656
- 946 2. Monteiro Júnior JGM, de Oliveira Cipriano Torres D, Filho DCS. Hematological Parameters as
947 Prognostic Biomarkers in Patients with Cardiovascular Diseases. *Curr Cardiol Rev*. 2019;15(4):274-282.
948 doi:10.2174/1573403x15666190225123544
- 949 3. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. *BMC Med*. 2013;11:117.
950 doi:10.1186/1741-7015-11-117
- 951 4. Libby P. Inflammation in atherosclerosis. *Nature*. 2002;420(6917):868-74.
952 doi:10.1038/nature01323
- 953 5. Michel JB, Martin-Ventura JL. Red Blood Cells and Hemoglobin in Human Atherosclerosis and
954 Related Arterial Diseases. *Int J Mol Sci*. 2020;21(18)doi:10.3390/ijms21186756
- 955 6. Businaro R, Tagliani A, Buttari B, Profumo E, Ippoliti F, Di Cristofano C, Capoano R, Salvati B,
956 Riganò R. Cellular and molecular players in the atherosclerotic plaque progression. *Ann N Y Acad Sci*.
957 2012;1262:134-41. doi:10.1111/j.1749-6632.2012.06600.x
- 958 7. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. *Thromb Haemost*.
959 2011;106(5):827-38. doi:10.1160/th11-08-0592
- 960 8. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple
961 parameter with multiple clinical applications. *Crit Rev Clin Lab Sci*. 2015;52(2):86-105.
962 doi:10.3109/10408363.2014.992064
- 963 9. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights
964 from the Framingham Study. *Jama*. 1992;267(9):1253-6.
- 965 10. Waterhouse DF, Cahill RA, Sheehan F, McCreery C. Prediction of calculated future cardiovascular
966 disease by monocyte count in an asymptomatic population. *Vasc Health Risk Manag*. 2008;4(1):177-87.
967 doi:10.2147/vhrm.2008.04.01.177
- 968 11. Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, Llàcer A. Low lymphocyte count and
969 cardiovascular diseases. *Curr Med Chem*. 2011;18(21):3226-33. doi:10.2174/092986711796391633
- 970 12. Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio G,
971 Grandi AM, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or
972 cardiac revascularisation. A systematic review on more than 34,000 subjects. *Thromb Haemost*.
973 2011;106(4):591-9. doi:10.1160/th11-02-0096
- 974 13. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in
975 cardiovascular diseases: An early indicator of prognosis? *Exp Mol Pathol*. 2019;110:104267.
976 doi:10.1016/j.yexmp.2019.104267
- 977 14. Williams PT. Quantile-Specific Heritability of Mean Platelet Volume, Leukocyte Count, and Other
978 Blood Cell Phenotypes. *Lifestyle Genom*. 2022;15(4):111-123. doi:10.1159/000527048
- 979 15. Lin BD, Carnero-Montoro E, Bell JT, Boomsma DI, de Geus EJ, Jansen R, Klufft C, Mangino M,
980 Penninx B, Spector TD, et al. 2SNP heritability and effects of genetic variants for
981 neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. *J Hum Genet*. 2017;62(11):979-988.
982 doi:10.1038/jhg.2017.76
- 983 16. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM, Tardaguila M,
984 Huffman JE, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell*.
985 2020;182(5):1214-1231.e11. doi:10.1016/j.cell.2020.08.008

- 986 17. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F,
987 Kostadima MA, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common
988 Complex Disease. *Cell*. 2016;167(5):1415-1429.e19. doi:10.1016/j.cell.2016.10.042
- 989 18. Zhang X, Johnson AD, Hendricks AE, Hwang SJ, Tanriverdi K, Ganesh SK, Smith NL, Peyser PA,
990 Freedman JE, O'Donnell CJ. Genetic associations with expression for genes implicated in GWAS studies
991 for atherosclerotic cardiovascular disease and blood phenotypes. *Hum Mol Genet*. 2014;23(3):782-95.
992 doi:10.1093/hmg/ddt461
- 993 19. Paaby AB, Rockman MV. The many faces of pleiotropy. *Trends Genet*. 2013;29(2):66-73.
994 doi:10.1016/j.tig.2012.10.010
- 995 20. Harshfield EL, Sims MC, Traylor M, Ouwehand WH, Markus HS. The role of haematological traits
996 in risk of ischaemic stroke and its subtypes. *Brain*. 2020;143(1):210-221. doi:10.1093/brain/awz362
- 997 21. He J, Jiang Q, Yao Y, Shen Y, Li J, Yang J, Ma R, Zhang N, Liu C. Blood Cells and Venous
998 Thromboembolism Risk: A Two-Sample Mendelian Randomization Study. *Front Cardiovasc Med*.
999 2022;9:919640. doi:10.3389/fcvm.2022.919640
- 1000 22. Yang Y, Zhou Y, Nyholt DR, Yap CX, Tannenber RK, Wang Y, Wu Y, Zhu Z, Taylor BV, Gratten J. The
1001 shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders. *Cell*
1002 *Genom*. 2023;3(2):100249. doi:10.1016/j.xgen.2022.100249
- 1003 23. den Harder AM, de Jong PA, de Groot MCH, Wolterink JM, Budde RPI, Işgum I, van Solinge WW,
1004 Ten Berg MJ, Lutgens E, Veldhuis WB, et al. Commonly available hematological biomarkers are
1005 associated with the extent of coronary calcifications. *Atherosclerosis*. 2018;275:166-173.
1006 doi:10.1016/j.atherosclerosis.2018.06.017
- 1007 24. Nikpay M, Mohammadzadeh S. Phenome-wide screening for traits causally associated with the
1008 risk of coronary artery disease. *J Hum Genet*. 2020;65(4):371-380. doi:10.1038/s10038-019-0716-z
- 1009 25. Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Red cell distribution width is
1010 associated with incident venous thromboembolism (VTE) and case-fatality after VTE in a general
1011 population. *Thromb Haemost*. 2015;113(1):193-200. doi:10.1160/th14-04-0335
- 1012 26. Bucciarelli P, Maino A, Felicetta I, Abbattista M, Passamonti SM, Artoni A, Martinelli I. Association
1013 between red cell distribution width and risk of venous thromboembolism. *Thromb Res*.
1014 2015;136(3):590-4. doi:10.1016/j.thromres.2015.07.020
- 1015 27. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. *Arterioscler*
1016 *Thromb Vasc Biol*. 2008;28(3):403-12. doi:10.1161/atvbaha.107.150474
- 1017 28. Hansen M, Zeddies S, Meinders M, di Summa F, van Alphen FPI, Hoogendijk AJ, Moore KS,
1018 Halbach M, Gutiérrez L, van den Biggelaar M, et al. The RNA-Binding Protein ATXN2 is Expressed
1019 during Megakaryopoiesis and May Control Timing of Gene Expression. *Int J Mol Sci*.
1020 2020;21(3)doi:10.3390/ijms21030967
- 1021 29. Nemkov T, Stephenson D, Erickson C, Dzieciatkowska M, Key A, Moore A, Earley EJ, Page GP,
1022 Lacroix IS, Stone M, et al. Regulation of kynurenine metabolism by blood donor genetics and biology
1023 impacts red cell hemolysis in vitro and in vivo. *Blood*. 2024;143(5):456-472.
1024 doi:10.1182/blood.2023022052
- 1025 30. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J,
1026 Baumert J, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array.
1027 *Hum Mol Genet*. 2013;22(8):1663-78. doi:10.1093/hmg/dd555
- 1028 31. Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L,
1029 Bharaj B, Sun L, et al. Genome-wide association identifies the ABO blood group as a major locus

- 1030 associated with serum levels of soluble E-selectin. *Arterioscler Thromb Vasc Biol.* 2009;29(11):1958-67.
1031 doi:10.1161/atvbaha.109.192971
- 1032 32. Prugger C, Luc G, Haas B, Morange PE, Ferrieres J, Amouyel P, Kee F, Ducimetiere P, Empana JP.
1033 Multiple biomarkers for the prediction of ischemic stroke: the PRIME study. *Arterioscler Thromb Vasc*
1034 *Biol.* 2013;33(3):659-66. doi:10.1161/atvbaha.112.300109
- 1035 33. Mendez-Barbero N, Yuste-Montalvo A, Nuñez-Borque E, Jensen BM, Gutiérrez-Muñoz C,
1036 Tome-Amat J, Garrido-Arandia M, Díaz-Perales A, Ballesteros-Martinez C, Laguna JJ, et al. The TNF-like
1037 weak inducer of the apoptosis/fibroblast growth factor-inducible molecule 14 axis mediates histamine
1038 and platelet-activating factor-induced subcutaneous vascular leakage and anaphylactic shock. *J Allergy*
1039 *Clin Immunol.* 2020;145(2):583-596.e6. doi:10.1016/j.jaci.2019.09.019
- 1040 34. Franchini M, Lippi G. Relative Risks of Thrombosis and Bleeding in Different ABO Blood Groups.
1041 *Semin Thromb Hemost.* 2016;42(2):112-7. doi:10.1055/s-0035-1564832
- 1042 35. Lee JY, Lee BS, Shin DJ, Woo Park K, Shin YA, Joong Kim K, Heo L, Young Lee J, Kyoung Kim Y, Jin
1043 Kim Y, et al. A genome-wide association study of a coronary artery disease risk variant. *J Hum Genet.*
1044 2013;58(3):120-6. doi:10.1038/jhg.2012.124
- 1045 36. Méndez-Barbero N, Gutiérrez-Muñoz C, Blázquez-Serra R, Martín-Ventura JL, Blanco-Colio LM.
1046 Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible
1047 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. *Cells.*
1048 2020;9(2)doi:10.3390/cells9020405
- 1049 37. Nagai M, Hirayama K, Ebihara I, Higuchi T, Imaizumi M, Maruyama H, Miyamoto Y, Kakita T,
1050 Ogawa Y, Fujita S, et al. Serum TNF-related and weak inducer of apoptosis levels in septic shock
1051 patients. *Ther Apher Dial.* 2011;15(4):342-8. doi:10.1111/j.1744-9987.2011.00966.x
- 1052 38. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan
1053 S, Målarstig A, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and
1054 cholesterol content in genome-wide analysis. *PLoS Genet.* 2009;5(11):e1000730.
1055 doi:10.1371/journal.pgen.1000730
- 1056 39. Ren L, Du W, Song D, Lu H, Hamblin MH, Wang C, Du C, Fan GC, Becker RC, Fan Y. Genetic ablation
1057 of diabetes-associated gene *Ccdc92* reduces obesity and insulin resistance in mice. *iScience.*
1058 2023;26(1):105769. doi:10.1016/j.isci.2022.105769
- 1059 40. Ellingsen TS, Lappégård J, Ueland T, Aukrust P, Brækkan SK, Hansen JB. Plasma hepcidin is
1060 associated with future risk of venous thromboembolism. *Blood Adv.* 2018;2(11):1191-1197.
1061 doi:10.1182/bloodadvances.2018018465
- 1062 41. Luo J, Thomassen JQ, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R. Neutrophil counts
1063 and cardiovascular disease. *Eur Heart J.* 2023;44(47):4953-4964. doi:10.1093/eurheartj/ehad649
- 1064 42. Weymann A, Ali-Hasan-Al-Saegh S, Sabashnikov A, Popov AF, Mirhosseini SJ, Nombela-Franco L,
1065 Testa L, Lotfaliani M, Zerrouh M, Liu T, et al. Platelets Cellular and Functional Characteristics in Patients
1066 with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. *Med Sci Monit Basic*
1067 *Res.* 2017;23:58-86. doi:10.12659/msmbr.902557
- 1068 43. Kim YK, Hwang MY, Kim YJ, Moon S, Han S, Kim BJ. Evaluation of pleiotropic effects among
1069 common genetic loci identified for cardio-metabolic traits in a Korean population. *Cardiovasc Diabetol.*
1070 2016;15:20. doi:10.1186/s12933-016-0337-1
- 1071 44. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al.
1072 Meta-analysis of genome-wide association studies identifies common variants associated with blood
1073 pressure variation in east Asians. *Nat Genet.* 2011;43(6):531-8. doi:10.1038/ng.834

- 1074 45. Zhang J, Guo Y, Zhao X, Pang J, Pan C, Wang J, Wei S, Yu X, Zhang C, Chen Y, et al. The role of
1075 aldehyde dehydrogenase 2 in cardiovascular disease. *Nat Rev Cardiol.* 2023;20(7):495-509.
1076 doi:10.1038/s41569-023-00839-5
- 1077 46. Wang W, Tang Y, Wang Y, Tascau L, Balcersek J, Tong W, Levine RL, Welch C, Tall AR, Wang N.
1078 LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. *Circ Res.*
1079 2016;119(6):e91-e103. doi:10.1161/circresaha.116.308955
- 1080 47. Bersenev A, Wu C, Balcersek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal
1081 and quiescence through direct interactions with JAK2. *J Clin Invest.* 2008;118(8):2832-44.
1082 doi:10.1172/jci35808
- 1083 48. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D,
1084 Erdmann J, Goldstein BA, et al. Large-scale association analysis identifies new risk loci for coronary
1085 artery disease. *Nat Genet.* 2013;45(1):25-33. doi:10.1038/ng.2480
- 1086 49. Sahadevan P, Allen BG. MK5: A novel regulator of cardiac fibroblast function? *IUBMB Life.*
1087 2017;69(10):785-794. doi:10.1002/iub.1677
- 1088 50. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, Sun P. A novel function of
1089 p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. *Mol Cell Biol.*
1090 2012;32(3):606-18. doi:10.1128/mcb.06301-11
- 1091 51. Page GP, Kanas T, Guo YJ, Lanteri MC, Zhang X, Mast AE, Cable RG, Spencer BR, Kiss JE, Fang F, et
1092 al. Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of
1093 hemolysis following blood storage. *J Clin Invest.* 2021;131(13)doi:10.1172/jci146077
- 1094 52. Erbilgin A, Civelek M, Romanoski CE, Pan C, Hagopian R, Berliner JA, Lusis AJ. Identification of
1095 CAD candidate genes in GWAS loci and their expression in vascular cells. *J Lipid Res.*
1096 2013;54(7):1894-905. doi:10.1194/jlr.M037085
- 1097 53. He M, Pei Z, Mohsen AW, Watkins P, Murdoch G, Van Veldhoven PP, Ensenauer R, Vockley J.
1098 Identification and characterization of new long chain acyl-CoA dehydrogenases. *Mol Genet Metab.*
1099 2011;102(4):418-29. doi:10.1016/j.ymgme.2010.12.005
- 1100 54. Xiao S, Qi M, Zhou Q, Gong H, Wei D, Wang G, Feng Q, Wang Z, Liu Z, Zhou Y, et al. Macrophage
1101 fatty acid oxidation in atherosclerosis. *Biomed Pharmacother.* 2024;170:116092.
1102 doi:10.1016/j.biopha.2023.116092
- 1103 55. Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in
1104 macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. *Atherosclerosis.*
1105 2006;188(2):323-30. doi:10.1016/j.atherosclerosis.2005.11.017
- 1106 56. Hao L, Ren M, Rong B, Xie F, Lin MJ, Zhao YC, Yue X, Han WQ, Zhong JQ. TWEAK/Fn14 mediates
1107 atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway. *J Cell Mol Med.*
1108 2018;22(9):4344-4353. doi:10.1111/jcmm.13724
- 1109 57. Inoue T, Matsunaga R, Sakai Y, Yaguchi I, Takayanagi K, Morooka S. Insulin resistance affects
1110 endothelium-dependent acetylcholine-induced coronary artery response. *Eur Heart J.*
1111 2000;21(11):895-900. doi:10.1053/euhj.1999.1872
- 1112 58. Neville MJ, Wittemans LBL, Pinnick KE, Todorčević M, Kaksonen R, Pietiläinen KH, Luan J, Scott RA,
1113 Wareham NJ, Langenberg C, et al. Regional fat depot masses are influenced by protein-coding gene
1114 variants. *PLoS One.* 2019;14(5):e0217644. doi:10.1371/journal.pone.0217644
- 1115 59. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpeläinen TO, Smith JA, Dehghan A, Dupuis
1116 J, Johnson AD, et al. Pleiotropic genes for metabolic syndrome and inflammation. *Mol Genet Metab.*
1117 2014;112(4):317-38. doi:10.1016/j.ymgme.2014.04.007

- 1118 60. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, Luo S, Li Z, Liu P, Han J, et al. Endothelial
1119 Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to
1120 Pharmacotherapies. *Pharmacol Rev.* 2021;73(3):924-967. doi:10.1124/pharmrev.120.000096
- 1121 61. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. *Nat Rev Cardiol.*
1122 2010;7(2):77-86. doi:10.1038/nrcardio.2009.228
- 1123 62. Cyr Y, Bozal FK, Barcia Durán JG, Newman AAC, Amadori L, Smyrnis P, Gourvest M, Das D, Gildea
1124 M, Kaur R, et al. The IRG1-itaconate axis protects from cholesterol-induced inflammation and
1125 atherosclerosis. *Proc Natl Acad Sci U S A.* 2024;121(15):e2400675121. doi:10.1073/pnas.2400675121
- 1126 63. Fuentes F, Palomo I, Fuentes E. Platelet oxidative stress as a novel target of cardiovascular risk in
1127 frail older people. *Vascul Pharmacol.* 2017;93-95:14-19. doi:10.1016/j.vph.2017.07.003
- 1128 64. Montenont E, Echagarruga C, Allen N, Araldi E, Suarez Y, Berger JS. Platelet WDR1 suppresses
1129 platelet activity and is associated with cardiovascular disease. *Blood.* 2016;128(16):2033-2042.
1130 doi:10.1182/blood-2016-03-703157
- 1131 65. Gleissner CA. Platelet-derived chemokines in atherogenesis: what's new? *Curr Vasc Pharmacol.*
1132 2012;10(5):563-9. doi:10.2174/157016112801784521
- 1133 66. Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C, Jandrot-Perrus M. The future of
1134 glycoprotein VI as an antithrombotic target. *J Thromb Haemost.* 2012;10(12):2418-27.
1135 doi:10.1111/jth.12009
- 1136 67. Jeney V, Balla G, Balla J. Red blood cell, hemoglobin and heme in the progression of
1137 atherosclerosis. *Front Physiol.* 2014;5:379. doi:10.3389/fphys.2014.00379
- 1138 68. Clemetson KJ, Clemetson JM. Platelet collagen receptors. *Thromb Haemost.* 2001;86(1):189-97.
- 1139 69. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ, McCarthy S,
1140 Schmidt EM, Sveinbjornsson G, et al. Biobank-driven genomic discovery yields new insight into atrial
1141 fibrillation biology. *Nat Genet.* 2018;50(9):1234-1239. doi:10.1038/s41588-018-0171-3
- 1142 70. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W,
1143 et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease
1144 in over a million participants. *Nat Genet.* 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6
- 1145 71. Ghouse J, Tragante V, Ahlberg G, Rand SA, Jespersen JB, Leinøe EB, Vissing CR, Trudsø L,
1146 Jonsdottir I, Banasik K, et al. Genome-wide meta-analysis identifies 93 risk loci and enables risk
1147 prediction equivalent to monogenic forms of venous thromboembolism. *Nat Genet.*
1148 2023;55(3):399-409. doi:10.1038/s41588-022-01286-7
- 1149 72. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman Å K, Wilk JB, Morley MP,
1150 Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights
1151 into the pathogenesis of heart failure. *Nat Commun.* 2020;11(1):163.
1152 doi:10.1038/s41467-019-13690-5
- 1153 73. van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, Vlachopoulou E,
1154 Ahlqvist E, Di Liao C, Sandholm N, et al. Genome-Wide Association Study of Peripheral Artery Disease.
1155 *Circ Genom Precis Med.* 2021;14(5):e002862. doi:10.1161/circgen.119.002862
- 1156 74. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q,
1157 Shi M, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. *Nature.*
1158 2022;611(7934):115-123. doi:10.1038/s41586-022-05165-3
- 1159 75. Tobin MD, Minelli C, Burton PR, Thompson JR. Commentary: development of Mendelian
1160 randomization: from hypothesis test to 'Mendelian deconfounding'. *Int J Epidemiol.* 2004;33(1):26-9.
1161 doi:10.1093/ije/dyh016

- 1162 76. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S,
1163 McVean GA, Abecasis GR. A global reference for human genetic variation. *Nature*.
1164 2015;526(7571):68-74. doi:10.1038/nature15393
- 1165 77. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh PR, Lareau C,
1166 Shores N, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant
1167 tissues and cell types. *Nat Genet*. 2018;50(4):621-629. doi:10.1038/s41588-018-0081-4
- 1168 78. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene
1169 regulation in humans. *Science*. 2015;348(6235):648-60. doi:10.1126/science.1262110
- 1170 79. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A fast and efficient
1171 colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nat Commun*.
1172 2021;12(1):764. doi:10.1038/s41467-020-20885-8
- 1173 80. Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Profile of
1174 Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant
1175 (22q11.2) Cases of Schizophrenia. *Schizophr Bull*. 2018;44(6):1350-1361. doi:10.1093/schbul/sbx174
- 1176 81. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing GWAS results
1177 by integrating pleiotropy and annotation. *PLoS Genet*. 2014;10(11):e1004787.
1178 doi:10.1371/journal.pgen.1004787
- 1179 82. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI,
1180 Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses.
1181 *Am J Hum Genet*. 2007;81(3):559-75. doi:10.1086/519795
- 1182 83. Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional causal effects and
1183 heritable confounding from GWAS summary statistics. *Nat Commun*. 2021;12(1):7274.
1184 doi:10.1038/s41467-021-26970-w
- 1185 84. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal
1186 Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. *Epidemiology*.
1187 2017;28(1):30-42. doi:10.1097/ede.0000000000000559
- 1188 85. Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite null hypothesis
1189 identifies novel shared loci between Type 2 Diabetes and Prostate Cancer. *PLoS Genet*.
1190 2020;16(12):e1009218. doi:10.1371/journal.pgen.1009218
- 1191 86. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of
1192 genetic associations with FUMA. *Nat Commun*. 2017;8(1):1826. doi:10.1038/s41467-017-01261-5
- 1193 87. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for
1194 estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310-5.
1195 doi:10.1038/ng.2892
- 1196 88. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC,
1197 Weng S, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome*
1198 *Res*. 2012;22(9):1790-7. doi:10.1101/gr.137323.112
- 1199 89. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z,
1200 Wang J, Ziller MJ, et al. Integrative analysis of 111 reference human epigenomes. *Nature*.
1201 2015;518(7539):317-30. doi:10.1038/nature14248
- 1202 90. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian
1203 test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS*
1204 *Genet*. 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383
- 1205 91. Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation

1206 analyses. *PLoS Genet.* 2020;16(4):e1008720. doi:10.1371/journal.pgen.1008720
1207 92. Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an eQTL-informed method to
1208 identify risk genes using genome-wide association study summary statistics. *Bioinformatics.*
1209 2021;37(16):2245-2249. doi:10.1093/bioinformatics/btab115
1210 93. Zhu H, Zhou X. Transcriptome-wide association studies: a view from Mendelian randomization.
1211 *Quant Biol.* 2021;9(2):107-121. doi:10.1007/s40484-020-0207-4
1212 94. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS
1213 data. *PLoS Comput Biol.* 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219
1214 95. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK.
1215 Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat*
1216 *Commun.* 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
1217 96. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME, Wray NR,
1218 Visscher PM, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait
1219 gene targets. *Nat Genet.* 2016;48(5):481-7. doi:10.1038/ng.3538
1220

Trait	Abbreviations	PubMed ID	Data source	N	N case	N control	Reference genome	Original no. of SNPs
Basophil count	BASO	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,204
Basophil percentage of leukocytes	BASO_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,870
Eosinophil count	EO	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,919
Eosinophil percentage of leukocytes	EO_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,115
Lymphocyte count	LYMPH	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,573
Lymphocyte percentage of leukocytes	LYMPH_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,258
Monocyte count	MONO	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,263,103
Monocyte percentage of leukocytes	MONO_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,263,840
Neutrophil count	NEUT	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,469
Neutrophil percentage of leukocytes	NEUT_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,508
leukocyte count	WBC	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,264,179

Mean platelet volume	MPV	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,253,304
Plateletcrit	PCT	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,253,096
Platelet component distribution width	PDW	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,254,093
Platelet count	PLT	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,253,708
Hematocrit	HCT	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,262,764
Hemoglobin measurement	HGB	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,261,840
High light scatter reticulocyte count	HLR	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,252,382
High light scatter percentage of red cells	HLR_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,251,884
Immature fraction of reticulocytes	IRF	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,249,976
Mean corpuscular hemoglobin	MCH	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,254,732
Mean corpuscular hemoglobin concentration	MCHC	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,262,882
Mean corpuscular	MCV	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,255,855

Mean reticulocyte volume	MRV	32888494	mmmary_statistics/UKBB_blood_cell_traits/ ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37 (hg19)	41,250,423
Mean spheric corpuscular volume	MSCV	32888494	mmmary_statistics/UKBB_blood_cell_traits/ ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37 (hg19)	41,251,154
Erythrocyte count	RBC	32888494	mmmary_statistics/UKBB_blood_cell_traits/ ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37 (hg19)	41,263,113
Red cell distribution width	RDW_CV	32888494	mmmary_statistics/UKBB_blood_cell_traits/ ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37 (hg19)	41,258,684
Reticulocyte count	RET	32888494	mmmary_statistics/UKBB_blood_cell_traits/ ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37 (hg19)	41,249,680
Reticulocyte fraction of red cells	RET_P	32888494	mmmary_statistics/UKBB_blood_cell_traits/ ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37 (hg19)	41,249,637
Atrial fibrillation	AF	30061737	https://www.ebi.ac.uk/gwas/studies/GCST006414	1,030,836	60,620	970,216	GRCh37 (hg19)	34,740,186
Coronary artery disease	CAD	36474045	https://cvd.hugeamp.org/datasets.html	1,165,690	181,522	984,168	GRCh37 (hg19)	20,073,070
Venous thromboembolism	VTE	36658437	https://www.decode.com/summarydata/	1,500,861	81,190	1,419,671	GRCh37 (hg19)	9,617,942
Heart failure	HF	31919418	https://www.ebi.ac.uk/gwas/studies/GCST009541	977,323	47,309	930,014	GRCh37 (hg19)	8,281,262
Peripheral artery disease	PAD	34601942	https://cvd.hugeamp.org/datasets.html	511,634	12,086	499,548	GRCh37 (hg19)	10,250,121
Stroke	Stroke	36180795	https://www.ebi.ac.uk/gwas/studies/GCST90104539	1,308,460	73,652	1,234,808	GRCh37 (hg19)	7,511,476

1222 **Table 1: Overview of 29 blood cell traits and 6 cardiovascular diseases included**
1223 **in this study**

1224 Note: Overview of 29 blood cell traits and 6 cardiovascular diseases, abbreviations as
1225 used throughout the manuscript, associated PubMed ID, Data source and Year of
1226 publication, the sample size, population and reference genome on which summary
1227 statistics are based, and the number of SNPs included in the original summary
1228 statistics, before we applied filtering.

1229 **Graphical abstract**





Figure1




1231

1232 **Figure 1: Estimated genome-wide genetic correlations between BCTs and CVDs**
 1233 **using LDSC**

1234 Genome-wide genetic associations between BCTs and CVDs. Orange or green
 1235 borders highlight significant genetic correlations (with estimates provided) if they
 1236 were FDR significant ($FDR < 0.05$) or nominally significant ($p < 0.05$), respectively.
 1237

Figure2



1238


1239 **Figure 2: Forest plot of the bidirectional causal relationship between BCTs and**
 1240 **CVDs**

1241 LHC-MR analysis was used to detect (a) forward (BCTs \rightarrow CVDs) and (b) reverse
 1242 (CVDs \rightarrow BCTs) causal effects. Estimates and 95% confidence intervals are shown as

1243 dots and error bars, respectively.

1244

Figure 3



1245

1246 **Figure 3: Overall landscape of the pleiotropic associations across three types of**
1247 **BCTs and six major CVDs**

1248 The three circular dendrograms included three BCTs (central points, including [a]
1249 leukocytes, [b] platelets, and [c] erythrocytes) and six CVDs (first circle), resulting in
1250 66, 24, and 84 trait pairs (second circle). A total of 156, 81, and 192 pleiotropic loci
1251 were identified in 43, 13, and 58 trait pairs for (a) leukocyte-CVDs, (b) platelet-CVDs,
1252 and (c) erythrocyte-CVDs, respectively (third circle). Significant pleiotropic genes
1253 were further identified by MAGMA and EMAGMA, and a total of 936 pleiotropic
1254 genes co-localized for paired traits. For trait pairs with more than three pleiotropic
1255 genes, we only displayed the top three pleiotropic genes according to the priority of
1256 candidate pleiotropic genes (fourth circle).


1257

Figure2

a

The forward MR analysis

medRxiv preprint doi: <https://doi.org/10.1101/2024.10.23.24315926>; this version posted October 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



b

The reverse MR analysis






Figure3


a



b




c



Shared Genetic Links

Blood Cell Traits and Cardiovascular Diseases

medRxiv preprint doi: <https://doi.org/10.1101/2024.10.23.24315926>; this version posted October 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Step1. Shared Genetic Architectures between BCTs and CVDs


Genome-wide genetic correlation
LDSC

Genome-wide Polygenic overlap
GPA

Local genetic correlation
LAVA



Step2. Shared Genetic Mechanisms between BCTs and CVDs



Mendelian randomization analysis: LHCMR

SNP-level analysis
Identification of potential pleiotropic loci:
PLACO and FUMA

Gene-level analysis
Identification of candidate pleiotropic genes:
MAGMA, e-MAGMA, and TWAS

Pathway-level analysis
Gene set and pathway enrichment analysis:
MAGMA and Metascape

Protein-level analysis
Proteome-wide Mendelian randomization analysis:
SMR and COLOC